CSL Cuts Profit Outlook, Flags $5 Billion in New Impairments
A technician inside the CSL Ltd. laboratory at the company’s headquarters in Melbourne, Australia.
Photographer: Carla Gottgens/BloombergCSL Ltd. cut its full-year outlook and flagged about $5 billion in additional impairments, saying a turnaround will take longer than expected after a review by its interim chief executive.
The Australian biotech now expects revenue of about $15.2 billion and net profit of about $3.1 billion for the year ending June 30, 2026 — both at constant currency — after demand trends and market pressures weighed on performance, the company said in a statement Monday. The forecast misses analyst estimates for about $15.8 billion in revenue and roughly $3.3 billion in profit, according to Bloomberg consensus data.